Evoke Pharma (Evoke Pharma) Forward Dividend Yield % : 0.00% (As of May. 26, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Evoke Pharma Forward Dividend Yield %?

As of today (2024-05-26), the Forward Annual Dividend Yield of Evoke Pharma is 0.00%.

As of today (2024-05-26), the Trailing Annual Dividend Yield of Evoke Pharma is 0.00%.

EVOK's Forward Dividend Yield % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 1.855
* Ranked among companies with meaningful Forward Dividend Yield % only.

Evoke Pharma's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Evoke Pharma's Forward Dividend Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Evoke Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evoke Pharma's Forward Dividend Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evoke Pharma's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Evoke Pharma's Forward Dividend Yield % falls into.

Evoke Pharma Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Evoke Pharma (NAS:EVOK) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Evoke Pharma Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Evoke Pharma's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Evoke Pharma (Evoke Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evoke Pharma Inc (NAS:EVOK) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

EV00:Germany

Address

420 Stevens Avenue, Suite 370, Solana Beach, CA, USA, 92075

Website

https://www.evokepharma.com

Evoke Pharma Inc is a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.

Executives

Vickie S Reed	director	TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David A Gonyer	director, officer: President and CEO	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Matthew J D'onofrio	officer: Exec VP, Chief Bus. Officer	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Lvp Gp Iii, Llc	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Kenneth J Widder	director, 10 percent owner	10070 BARNES CANYON ROAD, SAN DIEGO CA 92121
Dp Vii Associates Lp	10 percent owner	ONE PALMER SQ, STE 515, PRINCETON NJ 08542
Domain Parters Vii L P	10 percent owner	ONE PALMER SQUARE SUITE 515, PRINCETON NJ 08542
Nimesh Shah	10 percent owner	12481 HIGH BLUFF DRIVE, SUITE 150, SAN DIEGO CA 92130
Marilyn R. Carlson	officer: Chief Medical Officer	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Brian H Dovey	10 percent owner	ONE PALMER SQUARE, PRINCETON NJ 08542
Todd C Brady	director	C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075
Scott L Glenn	director
Lvpmc, Llc	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Partners Lp	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111
Lvp Iii Associates, L.p.	10 percent owner	ONE EMBARCADERO CENTER SUITE 4050, SAN FRANCISCO CA 94111